Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Melanoma and Peptides

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3148
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Melanoma and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Melanoma and Peptides.

    To find out more about Triple Analysis: Lymphoma, Melanoma and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Melanoma and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3SBio
4SC
7TM Pharma
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
Actelion
Adherex
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Baxter International
Bayer
Benitec
Bio-Medisinsk Innovasjon
BioAlliance Pharma
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biokine Therapeutics
Biolex
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celtic Pharma
Cephalon
Chemokine Therapeutics
Chiasma
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CSL
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Digna Biotech
DNAVEC
Dong-A
Dongkook Pharm
Dr Reddy’s
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Epizyme
Esperance Pharmaceuticals
Exelixis
Favrille
Flamel Technologies
Forma Therapeutics
Formula Pharmaceuticals
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GP Pharm
Gradalis
Gryphon Therapeutics
Hayashibara
Heber Biotec
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inotek
Inovio
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karyon-CTT
Kiadis
Kinex
Kirax
Kissei
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Nidus Laboratories
NIH
Non-industrial source
Novartis
Novogen
Noxxon
NPS Pharmaceuticals
Nycomed Pharma
Oasmia
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Otsuka
Oxford BioMedica
Pacific Biotech
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
PhiloGene
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Progen
ProNAi Therapeutics
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Serometrix
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
Spirogen
Sunesis
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Synageva BioPharma
Synta Pharmaceuticals
Tactic Pharma
Takeda
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
Unigene
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Vectura
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
WntResearch
XBiotech
Xencor
Xerion
Xigen
Yakult Honsha
York Pharma
Zelos Therapeutics
Zenotech
Zensun
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
ABT-510
AEB071
AEZS-108
afamelanotide
agatolimod
aldesleukin
alemtuzumab
ALT-801
amrubicin hydrochloride
angiopep+paclitaxel
APO-866
ARRY-438162
astuprotimut-r
Auto TAG vaccine
axitinib
bardoxolone methyl
belinostat
bevacizumab
bexarotene
BMS-663513
BMS-936558
bortezomib
brentuximab vedotin
Buparlisib
Cabozantinib
CB-10-01
CBP-501
cilengitide
cladribine
corticorelin acetate
cositecan
CT-011
dasatinib
decitabine
denenicokin
denileukin diftitox
deslorelin
dinaciclib
dovitinib lactate
E-75
E7449
elliptinium acetate
EMD-273063
emepepimut-S
endostatin
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
everolimus
Exherin
FPI-01
fresolimumab
galiximab
ganetespib
ganitumab
gefitinib
glembatumumab vedotin
golvatinib
goserelin
GSK-1120212
GSK-2118436
GV-1001
GVAX
GX-301
HBP-347
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
histrelin
ibritumomab tiuxetan
imatinib mesilate
imMucin
INCB-24360
inotuzumab ozogamicin
interferon
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
IPP-204106
irinotecan hydrochloride
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
Lambrolizumab
lanreotide
LEE-011
lenvatinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
LGX818
LipoVIL12
MDX-1379
MetXia
MGN-1601
mitoxantrone
MKC-1106-MT
MORAb-004
NAFB001
netupitant
nilotinib
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
OncoVAX
OTS-102
ozarelix
P276-00
panobinostat
pasireotide
pasireotide LAR
peginterferon alfa-2b
perifosine
pimasertib
pixantrone
plitidepsin
poly-ICLC
polyclonal antibody stimulator
pralatrexate
RAF-265
ramucirumab
razoxane
Reditux
retaspimycin
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
rituximab
romidepsin
romurtide
sagopilone
sargramostim
SCIB-1
selumetinib
sobuzoxane
sotatercept
sunitinib malate
Survivac
talminogene laherparepvec
temsirolimus
teniposide
tesetaxel
thalidomide
thymalfasin
TM-30339
trabedersen
tremelimumab
vapreotide, immediate-release
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vitespen
volociximab
VX-001
YM-155
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Melanoma and Peptides.
    To find out more about Triple Analysis: Lymphoma, Melanoma and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Melanoma and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lymphoma and Prostate Cancer. Learn More


Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


Lymphoma Drug Pathway Analyzer
There are today at least 563 targeted molecular therapies known to affect more than 244 specific intracellular signaling pathways for the treatment of lymphoma. The rational for this plethora of treatment strategies is based on our increasing understanding of the 288 drug targets that are included in this drug-pathway analyzing tool. No less than 267 of these have been recorded with mutations and 65 drug targets have mutations which have been causally implicated in cancer. Learn More


Triple Analysis: Apoptosis, Antibodies and Peptides
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Apoptosis and by the two compound strategies of Antibodies and Peptides. Learn More